Kezar Life Sciences Inc
(NQ:
KZR
)
0.7740
-0.0235 (-2.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kezar Life Sciences Inc
< Previous
1
2
3
4
5
6
Next >
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
Today 8:50 EDT
Kezar Life Sciences' zetomipzomib drug for lupus nephritis has been placed on clinical hold by the FDA following serious safety concerns. The company continues its autoimmune hepatitis trials while...
Via
Benzinga
Exposures
Product Safety
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
October 04, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
October 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
September 30, 2024
Via
Benzinga
Analyst Expectations for Kezar Life Sciences's Future
November 27, 2023
Via
Benzinga
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
September 30, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug
August 14, 2024
Kezar Life Sciences announced it has stopped enrollment in its phase 1 solid tumor drug study and will focus on developing zetomipzomib for autoimmune diseases.
Via
Benzinga
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024
August 13, 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 10, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
June 07, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024
May 09, 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 06, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
April 08, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
March 27, 2024
Discover how these stocks to make millionaires are leading in the gold, biotechnology, and application software industries.
Via
InvestorPlace
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
March 16, 2024
Learn how these penny stocks may yield a 5X return with their lead in application software and biotechnology.
Via
InvestorPlace
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
March 14, 2024
KZR stock results show that Kezar Life Sciences missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
March 14, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
March 08, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
March 02, 2024
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...
Via
Talk Markets
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
February 26, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
February 25, 2024
When you want to light your afterburners, these ideas will do the trick.
Via
InvestorPlace
3 Penny Stocks Poised for an Unbelievable 1,000% Jump
February 02, 2024
Discover penny stocks with the potential for a 1,000% leap: strategic growth, debt-free stability and pharmaceutical innovation await.
Via
InvestorPlace
As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits
January 08, 2024
Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson sees a silver lining.
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
December 18, 2023
Are you looking for the next bull run bonanza? Here are the top three penny stocks primed for explosive growth.
Via
InvestorPlace
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.